Pfizer Appoints Andrew Baum as Chief Strategy and Innovation Officer

On May 6, Pfizer announced the appointment of Andrew Baum as Chief Strategy and Innovation Officer and Executive Vice President. He will officially assume the position on June 3 and play a key role in advancing Pfizer's long-term corporate strategy initiatives. His responsibilities will include portfolio analysis and prioritization, business development activities, strengthening partnerships with the biotech ecosystem, and commercial evaluation of the research pipeline.

At the same time, Andrew Baum will also serve as the chairman of Pfizer's Portfolio Management Team. According to the press release, this team is Pfizer's highest-level management body, responsible for the portfolio management of the company's R&D pipeline and capital deployment.

Andrew Baum holds a Master’s degree in Physiological Sciences and Bachelor’s degrees in Medicine and Surgery from the University of Oxford, with dual expertise in both the healthcare industry and finance. He led Morgan Stanley's European pharmaceuticals business for 14 years and, in 2011, joined Citigroup as the Global Head of Healthcare and Managing Director of Equity Research.

After the COVID-19 dividend faded, finding new growth points became one of Pfizer's key strategies and a focal issue for the market. According to Pfizer's Q1 2024 financial report, the company's total revenue in the first quarter was $14.879 billion, with anti-cancer products being one of the main sources of income. Driven by products such as Vedtiniyuzumab (Padcev), Enzalutamide (Xtandi), and Lorlatinib (Lorbrena), Pfizer's oncology business revenue increased by 19% year-over-year.

In subsequent R&D, Pfizer's investment in the first quarter was $2.493 billion. As of now, Pfizer’s pipeline includes 113 clinical drugs under development, with 3 at the registration application stage, 37 in Phase III, 28 in Phase II, and 45 in Phase I.

In addition, Pfizer also closed its famous innovative R&D department — the Center for Therapeutic Innovation (CTI) last month. A spokesperson for Pfizer told the media that certain CTI projects would be integrated into other research units within Pfizer's R&D department, and that this decision was "part of a company-wide cost adjustment plan."